Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrast‐Induced Nephropathy: A Failure of Academic Clinical Science

Autor: Euan A. Sandilands, Jessica M. B. Rees, Khuram Raja, Neeraj Dhaun, Emma E. Morrison, Kirsty Hickson, Jonathan Wraight, Tanya Gray, Lesley Briody, Sharon Cameron, Adrian P. Thompson, Neil R. Johnston, Neal Uren, Jane Goddard, Andy Treweeke, Gordon Rushworth, David J. Webb, D. Nicholas Bateman, John Norrie, Ian L. Megson, Michael Eddleston

Publikováno v: Sandilands, E A, Rees, J MB, Raja, K, Dhaun, N, Morrison, E E, Hickson, K, Wraight, J, Gray, T, Briody, L, Cameron, S, Thompson, A P, Johnston, N R, Uren, N, Goddard, J, Treweeke, A, Rushworth, G, Webb, D J, Bateman, N, Norrie, J, Megson, I & Eddleston, M 2022, ' Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrast-Induced Nephropathy-A Failure of Academic Clinical Science ', Clinical pharmacology and therapeutics . https://doi.org/10.1002/cpt.2541

Contrast-induced nephropathy (CIN) is a major complication of imaging in patients with chronic kidney disease (CKD). The publication of an academic randomized controlled trial (RCT; n = 83) reporting oral (N)-acetylcysteine (NAC) to reduce CIN led to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf68dc214969b61a07ee0f99e8a36c71
https://doi.org/10.1002/cpt.2541